Levonorgestrel subdermal implants. A review of contraceptive efficacy and acceptability

Drugs

Volumn 55, Issue 6, 1998, Pages 861-887

  Coukell, Allan J ^a   Balfour, Julia A ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

CONTRACEPTIVE AGENT; LEVONORGESTREL; UNCLASSIFIED DRUG;

ARTICLE; BODY WEIGHT; BREAST FEEDING; CLINICAL TRIAL; CONTRACEPTION; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; FEMALE; FEMALE FERTILITY; HEADACHE; HUMAN; INTERMETHOD COMPARISON; INTRACRANIAL HYPERTENSION; MENSTRUATION DISORDER; META ANALYSIS; MOOD; PATIENT SATISFACTION; PREGNANCY RATE; SKIN MANIFESTATION; STROKE; SUBCUTANEOUS DRUG ADMINISTRATION; THROMBOTIC THROMBOCYTOPENIC PURPURA; VERTIGO; WEIGHT GAIN;

CONTRACEPTIVE AGENTS, FEMALE; CONTRACEPTIVES, ORAL, SYNTHETIC; DRUG IMPLANTS; DRUG INTERACTIONS; FEMALE; HUMANS; INFANT, NEWBORN; LEVONORGESTREL; PATIENT SATISFACTION; PREGNANCY; PREGNANCY OUTCOME; PROGESTERONE CONGENERS; SKIN ABSORPTION;

PURPURA;

EID: 0031834532     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-199855060-00019     Document Type: Article

References (154)

1. Coutinho E, da Silva AR, Mattos CER, et al. Contraception with long acting subdermal implants: I. An effective and acceptable modality in international clinical trials. Contraception 1978; 18 (4): 315-33
2. O'Connell BJ. New contraceptives in the 1990s. Curr Opin Pediatr 1995 Aug; 7: 371-5
3. Wyeth Laboratories Inc. Norplant® system (levonorgestrel implants): prescribing information. Philadelphia, PA, USA. 23 Jul 1996
4. Sivin I. International experience with NORPLANT® and NORPLANT®-2 contraceptives. Studies in Family Planning 1988; 19 (2): 81-94
5. Grubb GS, Moore D, Anderson NG. Pre-introductory clinical trials of Norplant® implants: a comparison of seventeen countries' experience. Contraception 1995 Nov; 52: 287-96
6. Sivin I, Lähteenmäki P, Mishell DR, et al. First week drug concentrations in women with levonorgestrel rod or Norplant® capsule implants ((registered trademark)). Contraception 1997; 56: 317-21
7. Brache V, Faundes A, Johansson E, et al. Anovulation, inadequate luteal phase and poor sperm penetration in cervical mucus during prolonged use of NORPLANT® implants. Contraception 1985; 31 (3): 261-73
8. Croxatto HB, Díaz S, Salvatierra AM, et al. Treatment of Norplant® subdermal implants inhibits sperm penetration through cervical mucus in vitro. Contraception 1987; 36 (2): 193-201
9. Brache V, Alvarez-Sanchez F, Faundes A, et al. Ovarian endocrine function through five years of continuous treatment with NORPLANT® subdermal contraceptive implants. Contraception 1990 Feb; 41: 169-77
10. Faundes A, Cochon L, Brache V, et al. Ovulatory dysfunction during continuous administration of low-dose levonorgestrel by subdermal implants. Fertil Steril 1991; 56: 27-31
11. Shaaban MM, Ghaneimah SA, Segal S, et al. Sonographic assessment of ovarian and endometrial changes during long-term Norplant use and their correlation with hormonal levels. Fertil Steril 1993; 59: 998-1002
12. Dunson TR, Blumenthal PD, Alvarez F, et al. Timing and onset of contraceptive effectiveness in Norplant implant users. Part 1. Changes in cervical mucus. Fertil Steril 1998; 69 (2): 258-66
13. Alvarez F, Brache V, Faundes A. Ultrasonographic and endocrine evaluation of ovarian function among Norplant® implants users with regular menses. Contraception 1996 Nov; 54: 275-9
14. Shoupe D, Horenstein J, Mishell Jr DR, et al. Characteristics of ovarian follicular development in Norplant users. Fertil Steril 1991 Apr; 55: 766-70
15. Shirley B, Bundren JC. Effects of levonorgestrel on capacity of mouse oocytes for fertilization and development. Contraception 1995 Mar; 51: 209-14
16. Singh K, Viegas OAC, Ratnam SS. A comparison of the effects of NORPLANT® capsules and NORPLANT®-2 rods on clinical chemistry: metabolic changes. Ann Acad Med Singapore 1990 Nov; 19: 833-6
17. Singh K, Viegas OAC, Loke DFM, et al. Effect of Norplant® implants on liver, lipid and carbohydrate metabolism. Contraception 1992 Feb; 45: 141-53
18. Croxatto HB, Diaz S, Roberston DN, et al. Clinical chemistry in women treated with levonorgestrel implants (Norplant™*) or a TCu 200 IUD. Contraception 1983; 27: 281-8
19. Shaaban MM, Elwan SI, El-Sharkawy MM, et al. Effect of subdermal levonorgestrel contraceptive implants, Norplant®*, on liver functions. Contraception 1984; 30 (5): 407-12
20. Otubu JAM, Towobola OA, Aisien AO, et al. Effects of NORPLANT® contraceptive subdermal implants on serum lipids and lipoproteins. Contraception 1993 Feb; 47: 149-59
21. Rabe T, Thuro HC, Goebel K, et al. Lipid metabolism in Norplant-2 users - a two-year follow-up study. Total cholesterol, triglycerides, lipoproteins and apolipoproteins. Contraception 1992 Jan; 45: 21-37
22. Cravioto MC, Durand M, Valles V, et al. Effects of norplant contraceptive implants on lipids, lipoproteins and apolipoproteins metabolism [abstract]. 10th International Congress of Endocrinology 1996 Jun 12; II: 847
23. Shamma FN, Rossi G, HajHassan L, et al. The effect of Norplant on glucose metabolism under hyperglycemic hyper-insulinemic conditions. Fertil Steril 1995 Apr; 63: 767-72
24. Koopersmith TB, Lobo RA. Insulin sensitivity is unaltered by the use of the Norplant® subdermal implant contraceptive. Contraception 1995 Mar; 51: 197-200
25. Konje JC, Otolorin EO, Ladipo OA. Changes in carbohydrate metabolism during 30 months on Norplant®. Contraception 1991 Aug; 44: 163-72
26. Konje JC, Odukoya OA, Otolorin EO, et al. Carbohydrate metabolism before and after Norplant® removal. Contraception 1992 Jul; 46: 61-9
27. Konje JC, Otolorin EO, Ladipo OA. The effect of continuous subdermal levonorgestrel (Norplant) on carbohydrate metabolism. Am J Obstet Gynecol 1992 Jan; 166: 15-9
28. Singh K, Viegas OAC, Koh SCL, et al. Effect of long-term use of Norplant® implants on haemostatic function. Contraception 1992 Mar; 45: 203-19
29. Lachnit-Fixson U. The role of triphasic levonorgestrel in oral contraception: a review of metabolic and hemostatic effects. Gynecol Endocrinol 1996 Jun; 10: 207-18
30. Prasad RNV, Koh S, Ratnam SS. Effects of three types of combined O.C. pills on blood coagulation, fibrinolysis and platelet function. Contraception 1989; 39 (4): 369-83
31. Kuhl H. Effects of progestogens on haemostasis. Maturitas 1995; 24: 1-19
32. Cromer BA, McArdle BJ, Mahan JD, et al. A prospective comparison of bone density in adolescent girls receiving depot medroxyprogesterone acetate (Depo-Provera), levonorgestrel (Norplant), or oral contraceptives. J Pediatr 1996 Nov; 129: 671-6
33. Naessen T, Olsson S-H, Gudmundson J. Differential effects of bone density of progestogen-only methods for contraception in premenopausal women. Contraception 1995; 52: 35-9
34. Taneepanichskul S, Intaraprasert S, Theppisai U, et al. Bone mineral density during long-term treatment with Norplant® implants and depot medroxyprogesterone acetate [625685]. Contraception 1997; 56: 153-5
35. Odlind V, Olsson S-E. Enhanced metabolism of levonorgestrel during phenytoin treatment in a woman with Norplant® implants. Contraception 1986; 33 (3): 257-61
36. Sivin I, Lähteenmäki P, Ranta S, et al. Levonorgestrel concentrations during use of levonorgestrel rod (LNG ROD) implants. Contraception 1997 Feb; 55: 81-5
37. Robertson DN, Sivin I, Nash HA, et al. Release rates of levonorgestrel from Silastic® capsules, homogeneous rods and covered rods in humans. Contraception 1983; 27: 483-95
38. Diaz S, Pavez M, Miranda P, et al. Long-term follow-up of women treated with Norplant® implants. Contraception 1987; 35 (6): 551-67
39. Diaz S, Pavez M, Herreros C, et al. Bleeding pattern, outcome of accidental pregnancies and levonorgestrel plasma levels associated with method failure in Norplant® implants users. Contraception 1986; 33 (4): 347-56
40. Olsson S-E, Odlind V. "Free levonorgestrel index® (FLI) is a better parameter than plasma level of levonorgestrel for predicting risk of pregnancy during use of subdermal contraceptive implants releasing levonorgestrel [abstract]. Steroids 1988; 52 (4): 407-8
41. Shaaban MM, Odlind V, Salem HT, et al. Levonorgestrel concentrations in maternal and infant serum during use of subdermal levonorgestrel contraceptive implants, Norplant®, by nursing mothers. Contraception 1986; 33 (4): 357-63
42. Shikary ZK, Betrabet SS, Patel ZM, et al. Transfer of levonorgestrel (LNG) administered through different drug delivery systems from the maternal circulation into the newborn infant's circulation via breast milk. Contraception 1987; 35 (5): 477-86
43. Diaz S, Herreros C, Juez G, et al. Fertility regulation in nursing women: VII. Influence of NORPLANT® levonorgestrel implants upon lactation and infant growth. Contraception 1985; 32 (1): 53-74
44. Mosby's Complete Drug Reference 7th edition. Levonorgestrel. Mosby: St. Louis. 1997
45. Haukkamaa M. Contraception by Norplant subdermal capsules is not reliable in epileptic patients on anticonvulsant treatment. Contraception 1996; 33 (6): 559-65
46. Roussel Laboratories Limited. Norplant*. ABPI Compendium of Data Sheets and Summaries of Product Characteristics 1996-97. Datapharm Publications Limited. London, 938
47. Croxatto HB, Díaz S, Pavez M, et al. Clearance of levonorgestrel from the circulation following removal of Norplant® subdermal implants. Contraception 1988; 38 (5): 509-23
48. Vekemans M, Delvigne A, Paesmans M. Continuation rates with a levonorgestrel-releasing contraceptive implant (Norplant®): a prospective study in Belgium. Contraception 1997; 56: 291-9
49. Affandi B, Santoso SSI, Djajadilaga, et al. Five-year experience with Norplant(R). Contraception 1987; 36 (4): 417-28
50. Akhter H, Dunson TR, Amatya RN, et al. A five-year clinical evaluation of Norplant contraceptive subdermal implants in Bangladeshi acceptors. Contraception 1993 Jun; 47: 569-82
51. Chompooutaweep S, Kochagarn E, Sirisumpan S, et al. Effectiveness of Norplant® implants among Thai women in Bangkok. Contraception 1996 Jan; 53: 33-6
52. Gu S-J, Du M-K, Zhang L-D, et al. A 5-year evaluation of NORPLANT contraceptive implants in China. Obstet Gynecol 1994 May; 83 (Pt 1): 673-8
53. Tseng LH, Lee T-Y, Yang Y-S, et al. Norplant® subdermal contraceptive system: experience in Taiwan. Contraception 1996 Mar; 53: 177-80
54. Chetri M, Bhatta A, Amatya RN, et al. Five-year evaluation of safety, efficacy and acceptability of Norplant implants in Nepal. Adv Contracept 1996 Sep; 12: 187-99
55. Cravioto M del C, Alvarado G, Canto-de-Cetina T, et al. A multicenter comparative study on the efficacy, safety, and acceptability of the contraceptive subdermal implants Norplant® and Norplant®-II. Contraception 1997 Jun; 55: 359-67
56. Salah M, Ahmed A-GM, Abo-Eloyoun M, et al. Five-year experience with NORPLANT® implants in Assiut, Egypt. Contraception 1987; 35 (6): 543-50
57. Singh K, Viegas OAC, Fong YF, et al. Acceptability of Norplant® implants for fertility regulation in Singapore. Contraception 1992 Jan; 45: 39-47
58. Fraser IS, Tiitinen A, Affandi B, et al. Norplant® consensus statement and background review. Contraception 1998 Jan; 57: 1-9
59. Polaneczky M, Slap G, Forke C, et al. The use of levonorgestrel implants (Norplant) for contraception in adolescent mothers. New Engl J Med 1994 Nov 3; 331: 1201-6
60. Berenson AB, Wiemann CM, Rickerr VI, et al. Contraceptive outcomes among adolescents prescribed Norplant implants versus oral contraceptives after one year of use. Am J Obstet Gynecol 1997 Mar; 176: 586-92
61. Fakeye O. Contraception with subdermal levonorgestrel implants as an alternative to surgical contraception at Ilorin, Nigeria. Int J Gynecol Obstet 1991 Aug; 35: 331-6
62. Dinerman LM, Wilson MD, Duggan AK, et al. Outcomes of adolescents using levonorgestrel implants vs oral contraceptives or other contraceptive methods. Arch Pediatr Adolesc Med 1995; 149: 967-72
63. Marangoni P, Cartagena S, Alvarado J, et al. Norplant® Implants and the TCu 200 IUD: a comparative study in Ecuador. Studies in Family Planning 1983; 14: 177-80
64. Singh K, Ratnam SS. A comparison of the clinical performance, contraceptive efficacy, reversibility and acceptability of Norplant implants and Ortho Gynae T380 intrauterine copper contraceptive device. Adv Contracept 1997; 13: 385-93
65. Peers T, Stevens JE, Graham J, et al. Norplant® implants in the UK: first year continuation and removals. Contraception 1996 Jun; 53: 345-51
66. Crosby UD, Schwarz BE, Gluck KL, et al. A preliminary report of Norplant® implant insertions in a large urban family planning program. Contraception 1993 Oct; 48: 359-66
67. Cullins VE, Remsburg RE, Blumenthal PD, et al. Comparison of adolescent and adult experiences with Norplant levonorgestrel contraceptive implants. Obstet Gynecol 1994 Jun; 83: 1026-32
68. Berenson AB, Wiemann CM. Patient satisfaction and side effects with levonorgestrel implant (Norplant) use in adolescents 18 years of age or younger. Pediatrics 1993 Aug; 92: 257-60
69. Berenson AB, Wiemann CM. Use of levonorgestrel implants versus oral contraceptives in adolescence: a case-control study. Am J Obstet Gynecol 1995 Apr; 172 (Pt 1): 1128-37
70. Blumenthal PD, Wilson LE, Remsburg RE, et al. Contraceptive outcomes among post-partum and post-abortal adolescents. Contraception 1994 Nov; 50: 451-60
71. Berenson AB, Wiemann CM. Contraceptive use among adolescent mothers at 6 months postpartum. Obstet Gynecol 1997 Jun; 89: 999-1005
72. Ruminjo JK, Amatya RN, Dunson TR, et al. Norplant® implants acceptability and user satisfaction among women in two African countries. Contraception 1996 Feb; 53: 101-7
73. Gu S, Sivin I, Du M, et al. Effectiveness of Norplant® implants through seven years: a large-scale study in China. Contraception 1995 Aug; 52: 99-103
74. Sivin I. Contraception with NORPLANT® implants. Hum Reprod 1994 Oct; 9: 1818-26
75. Potter LS. How effective are contraceptives? The determination and measurement of pregnancy rates. Obstet Gynecol 1996 Sep; 88 Suppl.: S13-23
76. Gu S, Du M, Zhang L, et al. A five-year evaluation of NORPLANT(Rm) II implants in China. Contraception 1994 Jul; 50: 27-34
77. Frank ML, DiMaria C. Levonorgestrel subdermal implants: contraception on trial. Drug Saf 1997; 17 (6): 360-8
78. World Health Organization Task Force for Epidemiological Research on Reproductive Health Special Programme of Research Development and Research Training in Human Reproduction. Progestogen-only contraceptives during lactation: I. infant growth. Contraception 1994; 50 (1): 35-53
79. World Health Organization Task Force for Epidemiological Research on Reproductive Health Special Programme of Research Development and Research Training in Human Reproduction. Progestogen-only contraceptives during lactation: II. infant development. Contraception 1994; 50 (1): 55-68
80. Affandi B, Karmadibrata S, Prihartono J, et al. Effect of Norplant on mothers and infants in the postpartum period. Adv Contracept 1986; 2 (4): 371-80
81. Shaaban MM, Salem HT, Abdullah KA. Influence of levonorgestrel contraceptive implants, NORPLANT®, initiated early postpartum upon lactation and infant growth. Contraception 1985; 32 (6): 623-35
82. World Health Organization. Improving access to quality care in family planning: medical eligibility criteria for contraceptive use. World Health Organization WHO/FRH/FPP/96.9. Geneva. 1996
83. Buckshee K, Chatterjee P, Dhall GI, et al. Return of fertility following discontinuation of Norplant-II subdermal implants. ICMR Task Force on Hormonal Contraception. Contraception 1995 Apr; 51: 237-42
84. Sivin I, Stern J, Diaz S, et al. Rates and outcomes of planned pregnancy after use of Norplant capsules, Norplant II rods, or levonorgestrel-releasing or copper TCu 380Ag intrauterine contraceptive devices. Am J Obstet Gynecol 1992 Apr; 166: 1208-13
85. Sivin I, Viegas O, Campodonico I, et al. Clinical performance of a new two-rod levonorgestrel contraceptive implant: a three-year randomized study with Norplant® implants as controls. Contraception 1997 Feb; 55: 73-80
86. Frank ML, Poindexter AN, Cornin LM, et al. One-year experience with subdermal contraceptive implants in the United States. Contraception 1993 Sep; 48: 229-43
87. Amatya R, Akhter H, McMahan J, et al. The effect of husband counseling on NORPLANT contraceptive acceptability in Bangladesh. Contraception 1994 Sep; 50: 263-73
88. Molland JR, Morehead DB, Baldwin DM, et al. Immediate postpartum insertion of the Norplant contraceptive device. Fertil Steril 1996 Jul; 66: 43-8
89. Phemister DA, Laurent S, Harrison Jr FNH. Use of Norplant contraceptive implants in the immediate postpartum period: safety and tolerance. Am J Obstet Gynecol 1995 Jan; 172 (Pt 1): 175-9
90. Shoupe D, Mishell DR Jr, Bopp BL, et al. The significance of bleeding patterns in Norplant implant users. Obstet Gynecol 1991; 77 (2): 256-60
91. Díaz J, Faundes A, Olmos P, et al. Bleeding complaints during the first year of Norplant® implants use and their impact on removal rate. Contraception 1996 Feb; 53: 91-5
92. Faúndes A, Alvarez Sanchez-F, Brache V, et al. Hormonal changes associated with bleeding during low dose progestogen contraception delivered by Norplant subdermal implants. Adv Contracept 1991; 7 (1): 85-94
93. Shaaban MM, Salah M, Zarzour A, et al. A prospective study of Norplant® implants and the TCu 380Ag IUD in Assiut, Egypt. Studies in Family Planning 1983; 14: 163-9
94. Diaz S, Croxatto HB, Pavez M, et al. Clinical assessment of treatments for prolonged bleeding in users of Norplant implants. Contraception 1990 Jul; 42: 97-109
95. Alvarez-Sanchez F, Brache V, Thevenin F, et al. Hormonal treatment for bleeding irregularities in Norplant implant users. Am J Obstet Gynecol 1996 Mar; 174: 919-22
96. Oloto EJ, Bromham DR, Walling M. Treatment of menstrual and non-menstrual side effects of Norplant: recommendations of an expert group. Br J Fam Plann 1995; 21 Suppl. 1: 3-5
97. Singleton-Yatawara G, Archer DF. Use of ethinyl estradiol (EE) to stop the prolonged bleeding associated with Norplant [abstract no. O-115]. Scientific Papers to be Presented at the Forty-Eighth Annual Meeting of the American Fertility Society. 1992 Nov 2-5. New Orleans. The American Fertility Society, Birmingham, Alabama: S52
98. Archer DF, Philput CA, Weber ME. Management of irregular uterine bleeding and spotting associated with Norplant®. Hum Reprod 1996 Oct; 11 Suppl. 2: 24-30
99. Boonkasemsanti W, Reinprayoon D, Pruksananonda K, et al. The effect of transdermal oestradiol on bleeding pattern, hormonal profiles and sex steroid receptor distribution in the endometrium of Norplant users. Hum Reprod 1996 Oct; 11 Suppl. 2: 115-23
100. Witjaksono J, Lau TM, Affandi B, et al. Oestrogen treatment for increased bleeding in Norplant users: preliminary results. Hum Reprod 1996 Oct; 11 Suppl. 2: 109-14
101. Alder JB, Fraunfelder FT, Edwards R. Levonorgestrel implants and intracranial hypertension [letter]. New Engl J Med 1995 Jun 22; 332: 1720-1
102. Moore LL, Valuck R, McDougall C, et al. A comparative study of one-year weight gain among users of medroxyprogesterone acetate, levonorgestrel implants, and oral contraceptives. Contraception 1995 Oct; 52: 215-9
103. Pasquale SA, Knuppel RA, Owens AG. Irregular bleeding, body mass index and coital frequency in Norplant® contraceptive users. Contraception 1994 Aug; 50: 109-16
104. Wagner KD, Berenson AB. Norplant-associated major depression and panic disorder. J Clin Psychiatry 1994 Nov; 55: 478-80
105. Wagner KD. Major depression and anxiety disorders associated with Norplant. J Clin Psychiatry 1996 Apr; 57: 152-7
106. Wysowski DK, Green L. Serious adverse events in Norplant users reported to the Food and Drug Administration's MedWatch Spontaneous Reporting System. Obstet Gynecol 1995 Apr; 85: 538-42
107. Sivin I. Serious adverse events in Norplant users reported to the Food and Drug Administration's medwatch spontaneous reporting system [letter]. Obstet Gynecol 1995 Aug; 86: 318-9
108. Wysowski DK, Green L. Serious adverse events in Norplant users reported to the Food and Drug Administration's medwatch spontaneous reporting system. Reply [letter]. Obstet Gynecol 1995 Aug; 86: 319-20
109. Chez RA. Serious adverse events in Norplant users related to the Food and Drug Administration's MedWatch Spontaneous Reporting System [letter]. Obstet Gynecol 1995 Jul; 86: 154-5
110. Hueston WJ, Locke KT. Norplant neuropathy: peripheral neurologic symptoms associated with subdermal contraceptive implants. J Family Pract 1995 Feb; 40: 184-6
111. Brittain J, Lange LS. Myasthenia gravis and levonorgestrel implant. Lancet 1995 Dec 9; 346: 1556
112. Vekemans M. Use of long-acting contraceptives [letter]. Lancet 1995 Oct 28; 346: 1165
113. Sarma SP, Hatcher RP. Neurovascular injury during removal of levonorgestrel implants. Am J Obstet Gynecol 1995; 172: 120-1
114. Zuber TJ, Dewitt DE, Patton DD. Skin damage associated with the Norplant contraceptive. J Family Pract 1992 May; 34: 613-6
115. Klavon SL, Grubb GS. Insertion site complications during the first year of Norplant® use. Contraception 1990; 41 (1): 27-37
116. Dunson TR, Amatya RN, Krueger SL. Complications and risk factors associated with the removal of Norplant implants. Obstet Gynecol 1995 Apr; 85: 543-8
117. Frank ML, Dilmore R, Ilegbodu AE, et al. Characteristics and experiences of American women electing for early removal of contraceptive implants. Contraception 1995 Sep; 52: 159-65
118. Oloto FJ, Regan S, Bromham DR. Norplant removal procedures -evidence of success of the insertion training programme. Br J Fam Plann 1996; 22 (3): 117-9
119. Gbolade BA. Post-Norplant® implants insertion anaphylactoid reaction: a case report. Contraception 1997 May; 55: 319
120. Post-Norplant® implants insertion anaphylactoid reaction: a case report. Editorial note. Contraception 1997 May; 55: 319-20
121. Davie JE, Walling MR, Mansour DJA, et al. Impact of patient counseling on acceptance of the levonorgestrel implant contraceptive in the United Kingdom. Clin Ther 1996 Jan-Feb; 18: 150-9
122. Diaz J, Rubin J, Faundes A, et al. Comparison of local signs and symptoms after the insertion of Norplant® implants with and without a scalpel. Contraception 1991 Sep; 44: 217-21
123. Nelson AL. Neutralizing pH of lidocaine reduces pain during Norplant® system insertion procedure. Contraception 1995 May; 51: 299-301
124. Blanchard PA, Kellerman RD. Alternative procedure for removal of Norplant (letter). Am Fam Physician 1994 Jun; 49: 1733
125. Praptohardjo U, Wibowo S. The "U" technique: a new method for Norplant implants removal. Contraception 1993 Dec; 48: 526-36
126. Sarma SP, Hatcher R. The Emory method: a modified approach to Norplant implants removal. Contraception 1994 Jun; 49: 551-6
127. Shihata AA, Salzetti RG, Schnepper FW, et al. Innovative technique for Norplant implants removal. Contraception 1995 Feb; 51: 83-5
128. Taneepanichskul S, Intaraprasert S, Chaturachinda K. Modified needle elevation technique for misplaced Norplant® implants removal. Contraception 1996 Aug; 54: 87-9
129. Miller L, Grice J. Intradermal proximal field block: an innovative anesthetic technique for levonorgestrel implant removal. Obstet Gynecol 1998; 91: 294-7
130. Blumenthal PD, Gaffikin L, Affandi B, et al. Training for Norplant implant removal: assessment of learning curves and competency. Obstet Gynecol 1997 Feb; 89: 174-8
131. Rosenberg MJ, Alvarez F, Barone MA, et al. A comparison of "U" and standard techniques for Norplant removal. Obstet Gynecol 1997 Feb; 89: 168-73
132. Sarma SP, Wamsher JG, Whitlock SW. Removal of deeply inserted, nonpalpable levonorgestrel (Norplant®) implants. Contraception 1996 Mar; 53: 159-61
133. Lang JF, Heine MW, Purdon TF. Use of needle localization for difficult Norplant removal (letter; comment). Am J Obstet Gynecol 1994 Oct; 171: 1161-2
134. Twickler DM, Schwarz BE. Imaging of the levonorgestrel implantable contraceptive device [letter]. Am J Obstet Gynecol 1992; 167: 572-3
135. Thurmond AS, Weinstein AS, Jones MK, et al. Localization of contraceptive implant capsules for removal. Radiology 1994; 193: 580-1
136. Kirk EP, Field CS. Difficult Norplant removal facilitated by fluoroscopy [letter]. Am J Obstet Gynecol 1993 Sep; 169: 748
137. Cozens NJA. Contraceptive-implants: high resolution ultrasonography facilitates removal. BMJ 1996 Oct 5; 313: 880
138. Thomsen RJ, Pasquale S, Nosher J. Ultrasonic visualization of NORPLANT® subdermal contraceptive devices. Int J Gynaecol Obstet 1985; 23 (3): 223-7
139. Cecil H, Reed D, Holtz J. Norplant removal facilitated by use of ultrasound for localization. J Family Pract 1995 Feb; 40: 182-3
140. Berg WA, Hamper UM. Norplant implants: sonographic identification and localization for removal. Am J Roentgenol 1995 Feb; 164: 419-20
141. Olsson S-E, Bakos O, Kurol M. How to localize 'missing' Norplant implants [abstract no. 89]. Adv Contracept 1992; 8 (3): 234-5
142. Weiner HM, DiMarcangelo MT, Heim JA, et al. Use of computed tompography guidance and mammographic hook wires to remove displaced, embedded contraceptive rods. J Am Osteopath Assoc 1996; 96: 422-3
143. Letterie GS, Garnaas M. Localization of "lost" Norplant capsules using compression film screen mammography. Obstet Gynecol 1995; 85 (5) II Suppl.: 886-7
144. Ortmeier BG, Sauer KA, Langley PC, et al. A cost-benefit analysis of four hormonal contraceptive methods. Clin Ther 1994 Jul-Aug; 16: 707-13
145. Ashraf T, Arnold SB, Maxfield Jr M. Cost-effectiveness of levonorgestrel subdermal implants: comparison with other contraceptive methods available in the United States. J Reprod Med 1994 Oct; 39: 791-8
146. Trussell J, Leveque JA, Koenig JD, et al. The economic value of contraception: a comparison of 15 methods. Am J Public Health 1995; 85: 494-503
147. Henshaw SK. Unintended pregnancy in the United States. Family Planning Perspectives 1998; 30 (1): 24-9,46
148. Hatcher RA, Trussell J, Stewart F, et al., editors. Contraceptive technology. 16th revised ed. New York, New York: Irvington Publishers, 1994
149. Kennedy KI, Short RV, Tully MR. Premature introduction of progestin-only contraceptive methods during lactation. Contraception 1997 Jun; 55: 347-50
150. Rosenthal SL, Biro FM, Kollar LM, et al. Experience with side effects and health risks associated with Norplant® implant use in adolescents. Contraception 1995 Nov; 52: 283-5
151. Crook D. Do different brands of oral contraceptives differ in their effects on cardiovascular disease? Br J Obstet Gynaecol 1997 May; 104: 516-20
152. Carr BR, Ory H. Estrogen and progestin components of oral contraceptives: relationship to vascular disease. Contraception 1997 May; 55: 267-72
153. Rosenberg L, Palmer JR, Sands MI, et al. Modern oral contraceptives and cardiovascular disease. Am J Obstet Gynecol 1997; 177: 707-15
154. Helmerhorst FM, Bloemenkamp KWM, Rosendaal FR, et al. Oral contraceptives and thrombotic disease: risk of venous thromboembolism. Thromb Haemost 1997 Jul; 78: 327-33